Related references
Note: Only part of the references are listed.MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2013)
IQGAP1 and its binding proteins control diverse biological functions
Colin D. White et al.
CELLULAR SIGNALLING (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Protein scaffolds in MAP kinase signalling
Matthew D. Brown et al.
CELLULAR SIGNALLING (2009)
IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesis
Colin D. White et al.
FEBS LETTERS (2009)
IQGAP1 is a scaffold for mitogen-activated protein kinase signaling
M Roy et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Share Paper
